Drug discovery research based on dinuclear platinum complexes with markedly high antitumor activity

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K07905
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Physical pharmacy
• Research Institution: Suzuka University of Medical Science
• Principal Investigator: Komeda Seiji 鈴鹿医療科学大学, 薬学部, 准教授 (60425056)
• Co-Investigator(Kenkyū-buntansha): 植村 雅子 鈴鹿医療科学大学, 薬学部, 助教 (70511997)
• Co-Investigator(Renkei-kenkyūsha): HIRAMOTO Keiichi 鈴鹿医療科学大学, 薬学部, 助教 (90251793) ; HARUSAWA Shinya 大阪薬科大学, 薬学部, 教授 (90167601) ; YONEYAMA Hiroki 大阪薬科大学, 薬学部, 助教 (90627001) ; YOSHIKAWA Yuko 同志社大学, 生命医科学部, 嘱託講師 (80291871)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 白金錯体 / 制がん剤 / DDS / 創薬 / 難治性がん / 白金製剤

Outline of Final Research Achievements

New tetrazolato-bridged dinuclear platinum(II) complexes were designed and synthesized to combine with DDS carrier or to introduce halogen into the complexes. Our in vivo study using mice with a subcutaneous homograft of Colon-26 colorectal cancer cells indicates that the tetrazolato-bridged dinuclear platinum(II) complexes are promising next-generation platinum-based drug candidates with markedly high and long-lasting antitumor efficacy. Indeed, the tumour growth in mice treated with the lead compound was much slower than that in mice treated with platinum-based drug oxaliplatin, which is used for the treatment of colorectal cancer. Even more remarkable, the lead compound exhibited high tumor-reduction effects against large-sized tumours, which sustained for a few weeks after a single intravenous dose of the compound.

Free Research Field

生物無機化学